A little more than one year after OurCrowd Qure launched a digital health fund and more than two years after Luminox Health partnered with Johns Hopkins to validate health tech, a managing partner of the fund and CEO of Luminox, Dr. Yossi Bahagon, offered an update in response to emailed questions.
Reducing Clinical and Staff Burnout with AI Automation
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
In the past year, the fund has made five investments. In addition to taking part in a Series C round for TytoCare this week, Qure has invested in AI-based medical image analysis and diagnostic business Zebra Medical Vision; genetic testing tracking business Kolgene; a cybersecurity business aimed at protecting connected medical devices at hospitals and smart medical homes called CyberMDX; and direct-to-consumer diabetes management platform Dario.
“We’re also exploring investments in two more companies – one is developing a machine learning-based medication personalization platform, and the other is targeting the opioid overconsumption crisis using neuro-remodeling achieved through a mobile-based augmented-reality solution,” Bahagon said.
Heard at HLTH 2024: Insights from Innovative Healthcare Executives
Executives from Imagine360, Verily, BrightInsight, Lantern, and Rhapsody shared their approaches to reducing healthcare costs and facilitating digital transformation.
In addition to his work with OurCrowd Qure, Bahagon also heads up Luminox Health, an Israeli digital health initiative that partnered with Johns Hopkins University a few years ago. The collaboration with Hopkins provides a beta testing and clinical trial site for companies through this pipeline.
Sweetch is the most recent company to finalize its clinical trial at Hopkins, according to Bahagon. The company developed an automated AI program for diabetes prediction and prevention. Hopkins’ division of endocrinology, diabetes, and metabolism carried out the trial. Findings are expected to be published later this year.
Luminox is also exploring another initiative with Hopkins that would be focused on addressing the lack of robust evidence validating and quantifying the value of digital medicine. The collaboration could involve setting up an evidence-based digital medicine research center.
Johns Hopkins didn’t immediately respond to questions about the potential new initiative.
Photo: LoveTheWind, Getty Images